MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Sonoma Pharmaceuticals Retained Earnings 2011-2026 | SNOA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -198 M | -194 M | -190 M | -184 M | -179 M | -172 M | -169 M | -157 M | -143 M | -152 M | -142 M | -134 M | -138 M | -132 M | -125 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -125 M | -198 M | -161 M |
Quarterly Retained Earnings Sonoma Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -200 M | -199 M | -198 M | -197 M | -196 M | -195 M | -194 M | -193 M | -192 M | -191 M | -190 M | -188 M | -186 M | -185 M | -184 M | -181 M | -180 M | -180 M | -179 M | -173 M | -172 M | -172 M | -171 M | -171 M | -170 M | -169 M | -169 M | -166 M | -164 M | -161 M | -157 M | -153 M | -149 M | -147 M | -143 M | -141 M | -157 M | -155 M | -152 M | -149 M | -146 M | -145 M | -142 M | -141 M | -135 M | -134 M | -134 M | -141 M | -141 M | -139 M | -138 M | -135 M | -133 M | -132 M | -132 M | -131 M | -128 M | -127 M | -125 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -125 M | -200 M | -162 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.2 | 1.27 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.68 | -0.56 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 13.92 | 5.86 % | $ 713 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.69 | 0.9 % | $ 402 M | Canada |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.48 | -0.12 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
-609 M | $ 5.72 | -3.3 % | $ 355 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 50.79 | -5.07 % | $ 1.66 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 1.38 | 9.13 % | $ 24.1 M |  China |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.66 | -1.19 % | $ 3.37 M | Canada |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 7.9 | 3.41 % | $ 2.88 B | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 5.14 | 8.9 % | $ 72.3 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 4.32 | -0.92 % | $ 569 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 4.23 | -0.25 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 26.13 | 3.24 % | $ 1.21 B | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 14.7 | -0.47 % | $ 2.02 B | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.95 | 2.85 % | $ 22.2 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.3 | 5.39 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 9.35 | -1.86 % | $ 664 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.58 | 1.64 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.64 | -0.12 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 8.95 | -3.35 % | $ 5.53 B | Canada |
 |
Veru
VERU
|
-295 M | $ 2.34 | 0.43 % | $ 316 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.0 | -2.0 % | $ 20.9 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 12.42 | 0.12 % | $ 15.1 B | USA |
 |
cbdMD
YCBD
|
-182 M | $ 1.11 | -3.91 % | $ 4.79 M | USA |
 |
Zomedica Corp.
ZOM
|
-171 M | - | -0.21 % | $ 98 M | USA |